Synthetic lethal hubs associated with vincristine resistant neuroblastoma
Abstract
Chemotherapy of cancer experiences a number of shortcomings including development of
* Corresponding authors
a
emergentec biodevelopment GmbH, Gersthofer Strasse 29-31, 1180 Vienna, Austria
Fax: +43 1 403 49 66 19
Tel: +43 1 403 49 66
b blue-drugs GmbH, Komturstrasse 3A, 60528 Frankfurt am Main, Germany
c Department of Molecular Genetics and the Crown Human Genome Center, Weizmann Institute of Science, Rehovot 76100, Israel
d ICREA-GRIB Complex Systems Lab, UPF, Parc de Recerca Biomedica Barcelona Dr. Aiguader 88, E-08003 Barcelona, Spain
e Institut für Medizinische Virologie, Klinikum der J.W. Goethe-Universität, Paul Ehrlich-Str. 40, 60596 Frankfurt am Main, Germany
f
Institute for Theoretical Chemistry, University of Vienna, Währingerstrasse 17, 1090 Vienna, Austria
E-mail:
bernd.mayer@univie.ac.at
Chemotherapy of cancer experiences a number of shortcomings including development of
R. Fechete, S. Barth, T. Olender, A. Munteanu, A. Bernthaler, A. Inger, P. Perco, A. Lukas, D. Lancet, J. Cinatl Jr., M. Michaelis and B. Mayer, Mol. BioSyst., 2011, 7, 200 DOI: 10.1039/C0MB00082E
To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.
Fetching data from CrossRef.
This may take some time to load.
Loading related content